Reading Time: < 1 minute
Gilead Sciences increased the U.S. prices of its top six antiviral drugs that treat HIV by 4.9 percent, according to financial and investment news site Barron’s.
The drugs, Atripla, Biktarvy, Descovy, Genvoya, Odefsey and Truvada, account for 95 percent of the revenue from Gilead’s HIV pipeline. Read More